Tevogen Bio Holdings Inc. expressed gratitude to the U.S. Department of Health and Human Services for convening Long COVID roundtables. Approximately 20 million adults in the U.S. are living with Long COVID, impacting health and economy. Tevogen’s investigational drug, TVGN 489, shows promise in addressing this public health crisis. CEO Ryan Saadi prioritizes SARS-CoV-2 consequences and is optimistic about TVGN 489’s impact. Professor Curtis L. Patton commends HHS leadership in addressing Long COVID and believes innovative therapies like TVGN 489 can make a difference. Tevogen is committed to developing personalized therapeutics through its ExacTcell™ platform.

Read more at GlobeNewswire: Tevogen Commends HHS for Addressing Long COVID, Emphasizes